Literature DB >> 9250267

Association of serum albumin and mortality risk.

P Goldwasser1, J Feldman.   

Abstract

Reduced levels of serum albumin concentration, a routine blood test, within the "normal" range have been reported to be associated with mortality risk. The literature is reviewed, with a focus on cohort studies meeting specified criteria, and findings are summarized. In studies of many populations, comprising healthy subjects and patients with acute or chronic illness, serum albumin concentration is inversely related to mortality risk in a graded manner over its entire range; the estimated increase in the odds of death ranges from 24% to 56% for each 2.5 g/l decrement in serum albumin concentration. The association predicts overall and cause-specific mortality including cardiovascular mortality. It is likely that albumin concentration is a highly sensitive indicator of preclinical disease and disease severity. A direct protective effect of the albumin molecule is suggested by the persistence of the association after adjustment for other known risk factors and preexisting illness, and after exclusion of early mortality. Although biologically plausible, there is no direct evidence for this hypothesis. Serum albumin concentration is an independent predictor of mortality risk and could be useful in the quantification of risk in a broad range of clinical and research settings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250267     DOI: 10.1016/s0895-4356(97)00015-2

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  143 in total

Review 1.  Human albumin solution for resuscitation and volume expansion in critically ill patients.

Authors:  Ian Roberts; Karen Blackhall; Phil Alderson; Frances Bunn; Gillian Schierhout
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Albumin-based nanoparticles as magnetic resonance contrast agents: II. Physicochemical characterisation of purified and standardised nanoparticles.

Authors:  A A Abdelmoez; G C Thurner; E A Wallnöfer; N Klammsteiner; C Kremser; H Talasz; M Mrakovcic; E Fröhlich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2010-07-14       Impact factor: 4.304

3.  Improved outcomes during cardiac surgery: a multifactorial enhancement of cardiopulmonary bypass techniques.

Authors:  Cody C Trowbridge; Alfred H Stammers; G Craig Wood; James D Murdock; Myra Klayman; Bianca R Yen; Edward Woods; Christian Gilbert
Journal:  J Extra Corpor Technol       Date:  2005-06

4.  Resuscitation using albumin in critically ill patients: research in patients at high risk of complications is now needed.

Authors:  J L Vincent
Journal:  BMJ       Date:  2006-11-18

Review 5.  The clinical use of albumin: the point of view of a specialist in intensive care.

Authors:  Pietro Caironi; Luciano Gattinoni
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

6.  The interaction of serum albumin with cholesterol containing lipid vesicles.

Authors:  Tanja Meierhofer; Jean M H van den Elsen; Petra J Cameron; Xavier Muñoz-Berbel; A Toby A Jenkins
Journal:  J Fluoresc       Date:  2009-07-31       Impact factor: 2.217

7.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

8.  The Best Predictors of Survival: Do They Vary by Age, Sex, and Race?

Authors:  Noreen Goldman; Dana A Glei; Maxine Weinstein
Journal:  Popul Dev Rev       Date:  2017-07-17

9.  Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.

Authors:  Ka Lai Yee; Huub Jan Kleijn; Thomas Kerbusch; Randolph P Matthews; Mary Beth Dorr; Kevin W Garey; Rebecca E Wrishko
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  Hyponatremia in the outpatient setting: clinical characteristics, risk factors, and outcome.

Authors:  Vildan Tasdemir; Ali Kemal Oguz; Irmak Sayın; Ihsan Ergun
Journal:  Int Urol Nephrol       Date:  2015-10-22       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.